Sponsors live webinar on October 19 with experts, patient advocates
The Preeclampsia Foundation announced today that the Centers for Disease Control and Prevention (CDC) awarded new funding for its MoMMA’s Voices program, a national coalition of patient advocacy organizations and individuals with "lived experience" –...
Abt Associates, together with subcontractors HealthBegins and the MoMMA’s Voices program of the Preeclampsia Foundation, will provide technical assistance and evaluation support to 36 HRSA-supported health centers who are implementing innovative appr...
Preeclampsia Foundation Canada has announced that Kylie Belchamber, PhD of University of Birmingham, and Serena Gundy, MD, FRCP of McMaster University, are their 2023 Vision Grant research award recipients. These highly competitive monetary awards re...
New preeclampsia research funded by Preeclampsia Foundation Peter J. Pappas grant finds distinct genetic traits of early-onset preeclampsia.
Preeclampsia survivors and their supporters will hit the pavement with a purpose on Saturday, August 26, as part of the fourth annual Promise Walk Wherever event sponsored by the Preeclampsia Foundation.
The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research for two, two-year grants of up to $200,000.
A new diagnostic test for preeclampsia has received approval from the US Food and Drug Administration for use in hospital settings.
Recommendations for high-risk expecting parents and health care providers to promote the prevention of preeclampsia, a leading cause of pregnancy-related death in the United States.
Preeclampsia Foundation Canada announced today at the Society for Maternal-Fetal Medicine’s (SMFM) 43rd Annual Meeting – The Pregnancy Meeting™ – that applications are now being accepted for its 2023 Vision Grant program.
The study is designed to potentially accelerate discovery of therapies for preeclampsia by designing placental cell lines that express variants of the APOL1 gene for drug screening.
Preeclampsia survivors and their supporters will hit the pavement with a purpose on Saturday, August 27, as part of the third annual Promise Walk Wherever event sponsored by the Preeclampsia Foundation.